Protalix BioTherapeutics Cultura de la Empresa

Mr. Tzvi Palash, M.Sc., B.Sc., has been the Chief Operating Officer of Protalix BioTherapeutics, Inc. (also known as Protalix Ltd.) since September 6, 2010. Mr. Palash served as the Chief Operating Officer of Colbar Lifescience Ltd. From 2006 to 2010, he served as a General Manager of ColBar LifeScience Ltd. From 2001 to 2006, he served as a Vice President of Operations of ColBar LifeScience. Mr. Palash served as a Member of the Global Aesthetic Management Team at the Consumer Group of Johnson & Johnson. He has over 20 years of experience in operations and manufacturing positions in leading Israeli biotechnology and pharmaceutical companies such as Interpharm, Teva, Pharmos and CTS. His experience covers plant building and management, product development and scale-up, QA/QC and managing relationships with FDA. Mr. Palash holds an M.Sc. in Biochemistry from the Hebrew University and a B.Sc. in Biology from the Tel Aviv University.

Dr. Yoseph Shaaltiel, Ph.D. founded Protalix BioTherapeutics, Inc. in 1993 and has been its Executive Vice President of Research and Development since December 31, 2006. Dr. Shaaltiel served as a Vice President Research and Development at Protalix BioTherapeutics, Inc. since December 31, 2006. Previously, Dr. Shaaltiel served as Research Associate at the MIGAL Technological Center. He also served as Deputy Head of the Biology Department of the Biological and Chemical Center of Israel's Defense Forces and as a Biochemist at Makor Chemicals Ltd. He has co-authored over twenty articles and abstracts on plant biochemistry and holds three patents. Makor Chemicals Ltd., leverages his vast experience and know-how, as he is a recognized expert in plant biochemistry processes and in plant tissue culture technologies. Dr. Shaaltiel has been a Director of Protalix BioTherapeutics, Inc. since December 31, 2006. He received his Ph.D. in Plant Biochemistry from the Weizmann Institute of Science. Dr. Shaaltiel was a Postdoctoral Fellow at the University of California at Berkeley and at Rutgers University in New Jersey. He holds Ms.C. in Biochemistry from the Hebrew University and a B.Sc. in Biology from the Ben Gurion University.

Mr. Yossi Maimon, CPA, MBA, has been the Chief Financial Officer of Protalix Biotherapeutics, Inc. since December 31, 2006. Mr. Maimon serves as the Chief Financial Officer of Global Operations of EngelInvest Group Ltd. He has been Vice President of Protalix Biotherapeutics, Inc. since December 31, 2006. He has been Treasurer and Secretary of Protalix Biotherapeutics, Inc. since December 31, 2006. He served as the Chief Financial Officer of Protalix Ltd., since October 15, 2006. He has over a decade of broad experience in corporate finance, accounting, taxation and SEC compliance. He served as the Chief Financial Officer of Way2call Communications Ltd., from 2000 to 2002., where he led the fund raising efforts, accounting issues and business development activities. Mr. Maimon served as the Chief Financial Officer of Colbar LifeScience LTD., from 2002 to 2006, where he lead all the corporate finance activities, fund raisings and legal aspects of Colbar LifeScience including the sale of it to Johnson and Johnson (JNJ). He served as a Controller of PEC, from 1998 to 2000, where he was responsible for SEC reporting and compliance and led the process of the delisting PEC and the merger into Discount Investment Bank. He is a Certified Public Accountant in the US (New York State) and Israel. Mr. Maimon holds a BA Degree in Accounting from City University Of New York and an MBA from Tel Aviv University.